Food Allergy Dx Firm AllerGenis, Luminex Ink Test Development Deal

Jan 16, 2019

|

NEW YORK (360Dx) – Food allergy diagnostic developer AllerGenis today announced a non-exclusive deal with Luminex for use of that company's xMAP technology to develop, market, and sell a precision food allergy diagnostic assay.

Financial and other terms of the deal were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

Food Allergy Dx Firm AllerGenis, Luminex Ink Test Development Deal

To read the full story....

Breaking News

Palmetto Expands Coverage for Decipher Biosciences Prostate Cancer Test

Cepheid Multiplex SARS-CoV-2, Flu, RSV Test Nabs FDA Emergency Use Authorization

ASU Team Wins $6M in Government Funding to Develop Rapid Saliva Testing System for Coronavirus

Biovica Files FDA 510(k) Submission for Breast Cancer Treatment Response Assay

Genetron, CStone Launch Clinical Trial to Develop CDx for Cancer Drug Avapritinib

Natera Cancer Liquid Biopsy Test Coverage to Expand Under New Draft LCD

Featured White Papers

What's Popular?

Roche SARS-CoV-2 Lateral Flow Antigen Test Could Meet Significant Demand

Commercial Coronavirus Antibody Tests Show Wide Variation in Accuracy in New Study

FDA Authorizes First COVID-19 Serology Test for Point-of-Care Use

Oxford Immunotec T-Cell Test for SARS-CoV-2 Being Evaluated in Public Health England Study

FDA Grants Emergency Use Authorization for Jiangsu Well Biotech Coronavirus Antibody Test

Sponsorships